Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 21, 2012; 18(35): 4823-4854
Published online Sep 21, 2012. doi: 10.3748/wjg.v18.i35.4823
Published online Sep 21, 2012. doi: 10.3748/wjg.v18.i35.4823
Natural history | |||
UC | CD1 | ||
Remission at any point in time | 50 | Relapse | 10-30 |
Overall intermittent course | 90 | Low activity | 15-20 |
Remission: 3-7 yr after diagnosis | 25 | Remission | 55-65 |
Yearly relapse | 18 | Chronic active | 13-20 |
Intermittent relapse | 51 | Chronic intermittent | 67-73 |
Remission for 10 yr | 13 | ||
10 yr colectomy rate | 10 | Surgery by 20 yr | > 75 |
Change in site of UC over 25 yr | Change in behavior | ||
LC→ C | 50 | NSNF → S | 27 |
C → LC | 75 | NSNF → F | 29 |
- Citation: Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854
- URL: https://www.wjgnet.com/1007-9327/full/v18/i35/4823.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i35.4823